| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ARDX Stock Overview
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 3 more risks
Ardelyx Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.59 |
| 52 Week High | US$8.25 |
| 52 Week Low | US$0.49 |
| Beta | 1.85 |
| 1 Month Change | -7.66% |
| 3 Month Change | -44.49% |
| 1 Year Change | -92.47% |
| 3 Year Change | -78.00% |
| 5 Year Change | -89.10% |
| Change since IPO | -95.79% |
Recent News & Updates
Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale
Ardelyx (NASDAQ:ARDX) stated Thursday it has signed a financing deal with HealthCare Royalty Partners to receive up to $20M on the the sale of its future royalties and sales milestones from Kyowa Kirin. Kyowa Kirin is Ardelyx' collaboration partner in Japan for the commercialization of its new drug Xphozah (tenapanor) to control serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Under the agreement terms, Ardelyx will receive from HealthCare Royalty a $10M upfront payment, an additional $5 following Kyowa Kirin's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan and $5M in the event net sales in Japan exceed a certain target level by 2025. "Together with the development milestones that may become due under the license agreement with Kyowa Kirin and the payments that may become due to Ardelyx under the recent amendment to the license agreement with Kyowa Kirin, we now have the opportunity to receive up to $85 million in non-dilutive capital based on the potential of tenapanor for hyperphosphatemia in Japan," said Mike Raab, president and chief executive officer of Ardelyx. Stock is up 7% in premarket trading on Thursday. Earlier: Ardelyx stock rises ~13% as kidney disease drug gets FDA panel meeting in November
Shareholder Returns
| ARDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.07% | -2.5% |
| 1Y | -92.5% | -25.1% | -21.2% |
Return vs Industry: ARDX underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: ARDX underperformed the US Market which returned -21.2% over the past year.
Price Volatility
| ARDX volatility | |
|---|---|
| ARDX Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 13.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ARDX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ARDX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 86 | Mike Raab | https://www.ardelyx.com |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.
Ardelyx Fundamentals Summary
| ARDX fundamental statistics | |
|---|---|
| Market Cap | US$85.89m |
| Earnings (TTM) | -US$153.08m |
| Revenue (TTM) | US$3.98m |
21.6x
P/S Ratio-0.6x
P/E RatioIs ARDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARDX income statement (TTM) | |
|---|---|
| Revenue | US$3.98m |
| Cost of Revenue | -US$7.40m |
| Gross Profit | US$11.39m |
| Other Expenses | US$164.47m |
| Earnings | -US$153.08m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 285.89% |
| Net Profit Margin | -3,843.36% |
| Debt/Equity Ratio | 40.7% |
How did ARDX perform over the long term?
See historical performance and comparisonValuation
Is ARDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ARDX?
Other financial metrics that can be useful for relative valuation.
| What is ARDX's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$85.89m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.7x |
| Enterprise Value/EBITDA | -0.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ARDX's PS Ratio compare to its peers?
| ARDX PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.2x | ||
CLGN CollPlant Biotechnologies | 76.2x | n/a | US$92.0m |
FBIO Fortress Biotech | 1.1x | 38.2% | US$85.9m |
LJPC La Jolla Pharmaceutical | 1.5x | 14.5% | US$79.7m |
MEIP MEI Pharma | 2.1x | 31.1% | US$77.2m |
ARDX Ardelyx | 21.6x | 54.5% | US$85.9m |
Price-To-Sales vs Peers: ARDX is expensive based on its Price-To-Sales Ratio (21.6x) compared to the peer average (20.2x).
Price to Earnings Ratio vs Industry
How does ARDX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ARDX is expensive based on its Price-To-Sales Ratio (21.6x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is ARDX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 21.6x |
| Fair PS Ratio | 256.7x |
Price-To-Sales vs Fair Ratio: ARDX is good value based on its Price-To-Sales Ratio (21.6x) compared to the estimated Fair Price-To-Sales Ratio (256.7x).
Share Price vs Fair Value
What is the Fair Price of ARDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ARDX ($0.59) is trading below our estimate of fair value ($35.11)
Significantly Below Fair Value: ARDX is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARDX's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Ardelyx forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
66.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARDX's revenue (54.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ARDX's revenue (54.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARDX is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Ardelyx performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-11.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARDX is currently unprofitable.
Growing Profit Margin: ARDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARDX is unprofitable, and losses have increased over the past 5 years at a rate of 11.3% per year.
Accelerating Growth: Unable to compare ARDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: ARDX has a negative Return on Equity (-238.48%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Ardelyx's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ARDX's short term assets ($114.2M) exceed its short term liabilities ($47.8M).
Long Term Liabilities: ARDX's short term assets ($114.2M) exceed its long term liabilities ($17.4M).
Debt to Equity History and Analysis
Debt Level: ARDX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ARDX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARDX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARDX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is Ardelyx current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARDX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ARDX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Mike Raab (57 yo)
13.33yrs
Tenure
US$4,230,994
Compensation
Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019 and its Chairman...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD4.23M) is above average for companies of similar size in the US market ($USD800.58K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: ARDX's management team is considered experienced (2.2 years average tenure).
Board Members
Experienced Board: ARDX's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ARDX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.5%.
Top Shareholders
Company Information
Ardelyx, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Ardelyx, Inc.
- Ticker: ARDX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$85.892m
- Shares outstanding: 144.60m
- Website: https://www.ardelyx.com
Number of Employees
Location
- Ardelyx, Inc.
- 400 Fifth Avenue
- Suite 210
- Waltham
- Massachusetts
- 2451
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/03 00:00 |
| End of Day Share Price | 2022/07/01 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.